Two new cancer pills show 'unprecedented' results in boosting survival rates and preventing recurrence

Ezra founder and CEO Emi Gal explains on'Fox & Friends Weekend' how artificial intelligence can'enhance' MRI scans, image quality, analysis, and comprehension. Potentially "practice-changing" results from two new cancer drug studies were introduced at the American Society of Clinical Oncology (ASCO)'s annual meeting this week in Chicago. For lung cancer patients, a drug called osimertinib -- taken by pill once daily -- was shown to reduce the risk of deaths by more than 50% in a long-running international study. For breast cancer patients, a new drug called ribociclib significantly increased survival rates and prevented recurring disease in a separate study. "Targeted therapies have been a major advance in treating deadly cancers," Dr. Marc Siegel, professor of medicine at NYU Langone Medical Center, told Fox News Digital.